R.BrownA
Weight loss-related findings: Individuals using GLP-1s for 18 months show the same pattern of reduced medical cost growth, reductions in hospitalizations due to MACE and lower claims incidence for a range of conditions
3 Sastre J, Pallard FV, Via J
Per KFF 2025, 43% of firms with 5,000-plus employees cover weight-loss GLP-1s (up from 28%), but only 30% of firms with 1,000 to 4,999 employees and 16% of firms with 200 to 999
Though there have been a number of case reports about melanoma emerging from moles that came during or after peptide use
Related research guides linked from this page include how-to-dose-cjc-1295-and-ipamorelin, cjc-1295-vs-ipamorelin, ipamorelin-fda-approval-status, list-of-peptides-and-what-they-do